NewAmsterdam Pharma Company NV has announced the results of the Phase 3 BROADWAY clinical trial, which were presented at the 2025 Alzheimer's Association International Conference $(AAIC)$ in Toronto. The trial evaluated the efficacy and safety of 10 mg obicetrapib compared to placebo in reducing Alzheimer's disease biomarkers. The analysis revealed that obicetrapib significantly reduced levels of plasma p-tau217, a key Alzheimer's disease biomarker, in both the full analysis set and in ApoE4 carriers. In APOE4/E4 carriers, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo. The findings suggest that CETP inhibition could be a potential novel approach for Alzheimer's prevention. These results build on obicetrapib's existing cardiometabolic profile, which has shown reductions in LDL-C, small dense LDL particles, Lipoprotein(a), and biomarkers associated with diabetes and kidney function in previous trials. NewAmsterdam Pharma plans to discuss these findings with regulatory authorities to determine potential next steps.